Events /// Investor News /// Investment Case /// Resources
Bayer is committed to providing sustainable solutions that address humanity’s most fundamental needs for essential healthcare and nutritious food. The Bayer Investor Relations Team is dedicated to creating transparency, fostering dialogue, and delivering value to our stakeholders.
Upcoming Events and Highlights
Investor News
Share Price / Index
May 22, 2025
Not intended for U.S. and UK Media
Eylea™ 8 mg approved in China for wet age-related macular degeneration
May 13, 2025
First-quarter performance:
Bayer confirms 2025 targets after solid start to the year
May 09, 2025
Not intended for U.S. and UK Media
Aflibercept 8 mg to treat macular edema following retinal vein occlusion submitted for approval in Japan
Discover More
